Andrew Baum
Stock Analyst at Citigroup
(1.27)
# 1660
Out of 5,329 analysts
48
Total ratings
52.00%
Success rate
14.77%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
MRK Merck & Co | Maintains: Buy | 125 115 | 84.08 | 36.77% | 9 | Feb 5, 2025 | |
PFE Pfizer | Maintains: Neutral | 30 29 | 24.18 | 19.93% | 6 | Jan 28, 2025 | |
BMY Bristol-Myers Squibb | Maintains: Neutral | 60 65 | 49.94 | 30.16% | 9 | Jan 28, 2025 | |
RPRX Royalty Pharma | Maintains: Buy | 60 40 | 32.82 | 21.88% | 2 | Oct 25, 2024 | |
ABBV AbbVie | Maintains: Strong Buy | 170 215 | 196.56 | 9.38% | 11 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 675 895 | 828.86 | 7.98% | 7 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 5 10 | 8.21 | 21.8% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 5, 2017 |